Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

The company expects to enroll approximately 160 patients across 40 centers worldwide.
  • Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and if successful, may enable a label amendment.  
  • Hand-Held Blood Phe Monitor: Several other programs are underway to expand and protect the market and to improve the ability of healthcare providers and patients to better manage PKU.  These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Regulatory approval and commercial availability of the handheld blood Phe monitor are expected in late 2011.
  • Firdapse: BioMarin expects to initiate a Phase III trial for LEMS in the U.S. in the second quarter of 2011.  If successful, NDA submission is expected in the first half of 2012, followed by approval by the end of 2012.

  • Mid-Stage Clinical Programs

  • PEG-PAL for PKU: Top-line results for the Phase II study, including a study comparing daily and weekly dosing and a formulation study are expected in mid-2011.  The company expects to initiate a Phase III trial in the first quarter of 2012.

  • Early-Stage Clinical Programs

  • BMN-673 (PARP inhibitor):  The company initiated a Phase I/II trial in January 2011.  The trial is an open-label study of once daily, orally administered BMN-673 in up to 70 patients ages 18 and older with advanced or recurrent solid tumors.  The primary objective of the study is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.
  • BMN-701 for Pompe Disease: BioMarin initiated a Phase I/II trial in Pompe patients in January 2011.  The trial is an open-label study to ev
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
    2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
    3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
    4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
    5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
    6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
    7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
    8. BioMarin Announces Third Quarter 2010 Financial Results
    9. BioMarin to Host a Research and Development Day on October 19th
    10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    11. BioMarin to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... , Sept. 2, 2014 Actavis plc (NYSE: ... Food and Drug Administration (FDA) has accepted for filing ... drug for the treatment of diarrhea and abdominal pain ... Syndrome (IBS-D).  Actavis, NDA for eluxadoline has been granted ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The NDA filing ...
    (Date:9/2/2014)... 2, 2014 ResMed (NYSE: RMD ) ... in the United States . The ... and user-friendly life support ventilators. ResMed,s ... ease of use for patients suffering from neuromuscular disease, ... childhood respiratory disorders. The U.S. launch comes on the ...
    (Date:9/2/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Administration (FDA) has granted orphan drug status to APD811 ... "The FDA Office of Orphan Products Development (OOPD) ... identify and designate drug candidates that could potentially treat ... of such products," said Craig M. Audet , ...
    Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
    ... The TandemHeart circulatory support system has been granted ... Contractor (MAC) serving over 1.3 million beneficiaries and over ... United States. "We are extremely pleased with ... TandemHeart system," said  Kraig McEwen, President and CEO of ...
    ... ELGX ), developer and marketer of minimally invasive ... release of its second quarter 2011 financial results, which will ... of the market. Endologix will hold a conference ... / 2:00 p.m. PT to discuss the results. The dial-in ...
    Cached Medicine Technology:TandemHeart Approved for Expanded Reimbursement 2Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011 2
    (Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
    (Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
    (Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
    (Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
    (Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
    Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
    ... health problems outside the lungs, researchers say , , WEDNESDAY, ... and long-term toxic effects on the heart and blood ... cause death, a new report says. , The ... issue of the Journal of the American College ...
    ... Physician Accuracy And ... Reduces Radiation Exposure for Patients, AUSTIN, Texas, Aug. ... Institute (TCAI) at St. David,s Medical Center became,the first ... -- an enhancement to the state-of-the art Hansen Robotic ...
    ... ("Assurant"),(NYSE: AIZ ), a premier provider of ... that Jane Meyer,has been appointed senior vice president, ... vice president, organizational development and,corporate communications effective immediately. ... and Mr. Walker will continue to report to ...
    ... Daily Dietary Supplements to Introduce Fashion Week ... Survival Kit at Verrier Runway Show, ... its,first-ever fashion partnership with breakout designer Ashleigh Verrier to,promote "Style ... healthy beauty during one of the most exciting and fast-paced,fashion ...
    ... the National Institutes of Health (NIH) have found a mechanism ... the development of autoimmune disease when turned off. The findings ... of autoimmunity and could also have implications for the development ... as cancer and HIV. The study paper appears online today ...
    ... strength, agility tied to brain damage, even in the ... -- Physical frailty among the elderly may be linked ... patients develop dementia, new research reveals. , The finding, ... the notion that motor impairment in the elderly is ...
    Cached Medicine News:Health News:Air Pollution Can Damage Heart, Blood Vessels, Too 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 3Health News:Assurant Announces Two Executive Appointments 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2Health News:Physical Frailty Could Predict Alzheimer's Disease 2Health News:Physical Frailty Could Predict Alzheimer's Disease 3
    ...
    ...
    Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
    ... Unique product designed for LASIK surgery and ... irrigate the corneal interface and/or stromal bed. ... flap and helps elevate the flap edge. ... (.40 x 22mm) Formed 9mm from end. ...
    Medicine Products: